Predictive factors associated with the therapeutic response in patients with polymyalgia rheumatica and remitting seronegative symmetrical synovitis with pitting edema syndrome

被引:1
作者
Tani, Kenji [1 ]
Kawaminami, Shingo [2 ]
Okura, Yoshihiro [1 ]
Tabata, Ryo [2 ]
Yuasa, Shino [3 ]
Nakanishi, Yoshinori [2 ]
Kawahito, Keisuke [4 ]
Inaba, Keisuke [2 ]
Inaba, Kaori [2 ]
Kondo, Keisuke [5 ]
Umetani, Kazumasa [6 ]
Miyatake, Akiko [7 ]
Suzuki, Yoshihiro [2 ]
Yamaguchi, Harutaka [2 ]
机构
[1] Tokushima Univ Hosp, Gen Med & Primary Care, 50 Kuramoto Cho, Tokushima 7708503, Japan
[2] Tokushima Univ, Dept Gen Med, Inst Biomed Sci, Grad Sch, Tokushima, Japan
[3] Tokushima Prefectural Cent Hosp, Tokushima, Japan
[4] Yoshinogawa Med Ctr, Tokushima, Japan
[5] Ehime Prefectural Cent Hosp, Matsuyama, Ehime, Japan
[6] Tokyo Bei Urayasu IchikawaMed Ctr, Chiba, Japan
[7] Naruto Yamakami Hosp, Tokushima, Japan
关键词
PMR; RS3PE; Syndrome; C-reactive protein; prednisolone; relapse; GIANT-CELL ARTERITIS; RHEUMATISM/AMERICAN COLLEGE; CLINICAL CHARACTERISTICS; CLASSIFICATION CRITERIA; EUROPEAN LEAGUE; 1ST YEAR; MANAGEMENT; OUTCOMES; PROGNOSIS;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Polymyalgia rheumatica (PMR) and remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome are common inflammatory rheumatic diseases in the elderly. In this study, we investigate predictive factors which correspond to subsequent disease control of PMR and RS3PE syndrome. Twenty four patients, which contained 18 PMR and 6 RS3PE syndrome, were treated with initial dosages of 10-20 mg per day oral prednisolone, and the dosage of prednisolone was then tapered. Significantly higher initial CRP was observed in patients with poor disease control than in those with good disease control afterwards. The number of patients with negative CRP after 4 weeks was significantly more in patients with good disease control after 1 year than in those with poor disease control. Patients were shown to be in good disease control status after 1 year when CRP after 4 weeks became negative even if they had initial high CRP. Our study clarify that to make CRP negative after 4 weeks is associated with subsequent suppression of the disease activity and with decreased dosages of corticosteroids.
引用
收藏
页码:112 / 118
页数:7
相关论文
共 33 条
[1]   MYALGIC SYNDROME WITH CONSTITUTIONAL EFFECTS POLYMYALGIA RHEUMATICA [J].
BARBER, HS .
ANNALS OF THE RHEUMATIC DISEASES, 1957, 16 (02) :230-237
[2]   EVALUATION OF CRITERIA FOR POLYMYALGIA RHEUMATICA [J].
BIRD, HA ;
ESSELINCKX, W ;
DIXON, ASJ ;
MOWAT, AG ;
WOOD, PHN .
ANNALS OF THE RHEUMATIC DISEASES, 1979, 38 (05) :434-439
[3]   Polymyalgia Rheumatica and Giant Cell Arteritis A Systematic Review [J].
Buttgereit, Frank ;
Dejaco, Christian ;
Matteson, Eric L. ;
Dasgupta, Bhaskar .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 315 (22) :2442-2458
[4]   Is the course of steroid-treated polymyalgia rheumatica more severe in women? [J].
Cimmino, Marco A. ;
Parodi, Massimiliano ;
Caporali, Roberto ;
Montecucco, Carlomaurizio .
BASIC AND CLINICAL ASPECTS OF NEUROENDOCRINE IMMUNOLOGY IN RHEUMATIC DISEASES, 2006, 1069 :315-321
[5]   The correct prednisone starting dose in polymyalgia rheumatica is related to body weight but not to disease severity [J].
Cimmino, Marco A. ;
Parodi, Massimiliano ;
Montecucco, Carlomaurizio ;
Caporali, Roberto .
BMC MUSCULOSKELETAL DISORDERS, 2011, 12
[6]   Contribution of the Polymyalgia Rheumatica Activity Score to Glucocorticoid Dosage Adjustment in Everyday Practice [J].
Cleuziou, Caroline ;
Binard, Aymeric ;
De Bandt, Michel ;
Berthelot, Jean-Marie ;
Saraux, Alain .
JOURNAL OF RHEUMATOLOGY, 2012, 39 (02) :310-313
[7]  
Dasgupta B, 2008, J RHEUMATOL, V35, P270
[8]   2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative [J].
Dasgupta, Bhaskar ;
Cimmino, Marco A. ;
Maradit-Kremers, Hilal ;
Schmidt, Wolfgang A. ;
Schirmer, Michael ;
Salvarani, Carlo ;
Bachta, Artur ;
Dejaco, Christian ;
Duftner, Christina ;
Jensen, Hanne Slott ;
Duhaut, Pierre ;
Poor, Gyula ;
Kaposi, Novak Pal ;
Mandl, Peter ;
Balint, Peter V. ;
Schmidt, Zsuzsa ;
Iagnocco, Annamaria ;
Nannini, Carlotta ;
Cantini, Fabrizio ;
Macchioni, Pierluigi ;
Pipitone, Nicolo ;
Del Amo, Montserrat ;
Espigol-Frigole, Georgina ;
Cid, Maria C. ;
Martinez-Taboada, Victor M. ;
Nordborg, Elisabeth ;
Direskeneli, Haner ;
Aydin, Sibel Zehra ;
Ahmed, Khalid ;
Hazleman, Brian ;
Silverman, Barbara ;
Pease, Colin ;
Wakefield, Richard J. ;
Luqmani, Raashid ;
Abril, Andy ;
Michet, Clement J. ;
Marcus, Ralph ;
Gonter, Neil J. ;
Maz, Mehrdad ;
Carter, Rickey E. ;
Crowson, Cynthia S. ;
Matteson, Eric L. .
ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (04) :484-492
[9]   BSR and BHPR guidelines for the management of polymyalgia rheumatica [J].
Dasgupta, Bhaskar ;
Borg, Frances A. ;
Hassan, Nada ;
Barraclough, Kevin ;
Bourke, Brian ;
Fulcher, Joan ;
Hollywood, Jane ;
Hutchings, Andrew ;
Kyle, Valerie ;
Nott, Jennifer ;
Power, Michael ;
Samanta, Ash .
RHEUMATOLOGY, 2010, 49 (01) :186-190
[10]   Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities [J].
Dejaco, Christian ;
Brouwer, Elisabeth ;
Mason, Justin C. ;
Buttgereit, Frank ;
Matteson, Eric L. ;
Dasgupta, Bhaskar .
NATURE REVIEWS RHEUMATOLOGY, 2017, 13 (10) :578-592